11147 studies found for:    NCI
Show Display Options
Rank Status Study
21 Not yet recruiting Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Carboplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
22 Withdrawn Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Conditions: Adult Solid Neoplasm;   Estrogen Receptor Negative;   Fallopian Tube Serous Neoplasm;   HER2/Neu Negative;   Ovarian Serous Adenocarcinoma;   Ovarian Serous Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
23 Recruiting Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Conditions: Breast Carcinoma;   Neuropathy
Intervention: Other: Laboratory Biomarker Analysis
24 Recruiting Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
Conditions: Breast Carcinoma;   Cardiovascular Complication
Intervention: Other: Laboratory Biomarker Analysis
25 Recruiting Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Conditions: Breast Carcinoma;   Hypertension
Intervention: Other: Laboratory Biomarker Analysis
26 Suspended Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Conditions: High Grade Sarcoma;   Metastatic Leiomyosarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Myxofibrosarcoma;   Recurrent Leiomyosarcoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Synovial Sarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Drug: Sapanisertib
27 Not yet recruiting Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
Conditions: Estrogen Receptor Positive;   Postmenopausal;   Stage 0 Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer
Interventions: Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery
28 Recruiting Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
29 Recruiting VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Adult Solid Neoplasm;   Metastatic Malignant Neoplasm;   Refractory Malignant Neoplasm;   Unresectable Malignant Neoplasm
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
30 Recruiting Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
31 Recruiting Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Veliparib
32 Not yet recruiting Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Serous Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis
33 Recruiting Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vulvar Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB Vulvar Cancer;   Stage IB2 Cervical Cancer;   Stage II Vulvar Cancer;   Stage IIA1 Cervical Cancer;   Stage IIA2 Cervical Cancer;   Stage IIB Cervical Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Vulvar Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vulvar Cancer;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: High-Dose Rate Brachytherapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Triapine
34 Recruiting Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Conditions: AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Hepatocellular Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Hepatocellular Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Hepatocellular Carcinoma;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma;   Stage IVA Hepatocellular Carcinoma;   Stage IVB Hepatocellular Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
35 Recruiting VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Lung Carcinoma Metastatic in the Brain;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Radiation: Whole-Brain Radiotherapy
36 Not yet recruiting Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma
Conditions: Metastatic Melanoma;   Recurrent Melanoma of the Skin;   Stage IV Skin Melanoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study
37 Recruiting Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
Conditions: Erythroplakia;   Hyperplasia;   Mild Dysplasia;   Moderate Dysplasia;   Oral Cavity Carcinoma;   Oral Leukoplakia;   Severe Dysplasia
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride
38 Recruiting AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Other: Fluorothymidine F-18;   Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
39 Recruiting Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
Conditions: Human Papillomavirus Infection;   No Evidence of Disease
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
40 Recruiting Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years